Epstein–Barr virus latent membrane protein 1 (LMP1 ) is an Epstein–Barr virus (EBV) protein that regulates its own expression and the expression of human genes.[ 1] It has a molecular weight of approximately 63 kDa , and its expression induces many of the changes associated with EBV infections and activation of primary B cells .[ 2] LMP1 is the best-documented oncoprotein of the EBV latent gene products , as it is expressed in most EBV-related human cancers[ 3] such as the various malignant Epstein-Barr virus-associated lymphoproliferative diseases .[ 4]
The structure of LMP1 consists of a short cytoplasmic terminal tail , six trans-membrane domains , and a long cytoplasmic C-terminus , which contains three activating domains: CTARt, CTAR2, and CTAR3. Each CTAR domain contains an amino acid sequence that serves as a recognition site for cellular adaptors to bind and trigger a series of signal transduction pathways that can lead to a change in gene expression .[ 5]
LMP-1 is a functional homologue of tumor necrosis factor [ 6] and mediates signaling through the nuclear factor-κB pathway, mimicking CD40 receptor signaling.[ 1] [ 3]
It is often found in the malignant Reed–Sternberg cells of Hodgkin lymphoma ,[ 7] [ 8] the malignant B cells of EBV-associated B cell lymphatic cancers , and the malignant NK cells of NK/T cell lymphatic cancers .[ 4]
References
^ a b Pratt, Z; Zhang, J; Sugden, B. (2012). "The latent membrane protein 1 (LMP1) oncogene of Epstein–Barr virus can simultaneously induce and inhibit apoptosis in B cells" . Journal of Virology . 86 (8): 4380– 4393. doi :10.1128/JVI.06966-11 . PMC 3318665 . PMID 22318153 .
^ Gupta (2011). "Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines" . Retrovirology . 8 (1): 39. doi :10.1186/1742-4690-8-39 . PMC 3118346 . PMID 21592361 .
^ a b Ersing, I; Bernhardt, K; Gewurz, BE (Jun 21, 2013). "NF-κB and IRF7 pathway activation by Epstein-Barr virus Latent Membrane Protein 1" . Viruses . 5 (6) (6 ed.): 1587– 606. doi :10.3390/v5061587 . PMC 3717723 . PMID 23793113 .
^ a b Rezk SA, Zhao X, Weiss LM (June 2018). "Epstein - Barr virus - associated lymphoid proliferations, a 2018 update". Human Pathology . 79 : 18– 41. doi :10.1016/j.humpath.2018.05.020 . PMID 29885408 . S2CID 47010934 .
^ Li, H.; Chang, Y. (2003). "Epstein–barr virus latent membrane protein 1: Structure and functions". J. Biomed. Sci . 10 (5): 490– 504. doi :10.1159/000072376 . PMID 12928589 . S2CID 202646382 .
^ Cameron, J. E.; Yin, Q; Fewell, C; Lacey, M; McBride, J; Wang, X; Lin, Z; Schaefer, B. C.; Flemington, E. K. (2008). "Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways" . Journal of Virology . 82 (4): 1946– 58. doi :10.1128/JVI.02136-07 . PMC 2258704 . PMID 18057241 .
^ Herling M, Rassidakis GZ, Medeiros LJ, et al. (June 2003). "Expression of Epstein–Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome" . Clin. Cancer Res . 9 (6): 2114– 20. PMID 12796376 .
^ Andersson J (May 2006). "Epstein–Barr virus and Hodgkin's lymphoma". Herpes . 13 (1): 12– 6. PMID 16732997 .